CXCL12-stimulated lymphocytes produce secondary stimulants that affect the surrounding cell chemotaxis

Kaoru Kurowarabe a, b, Masataka Endo a, b, Daichi Kobayashi c, Haruko Hayasaka a, b, d, *

a Department of Science, Graduate School of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan
b Laboratory of Immune Molecular Function, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan
c Department of Immunology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata, 951-8510, Japan
d Research Institute for Science and Technology, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan

Corresponding author. Department of Science, Graduating School of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka, 577-8502, Japan.
E-mail address: hhayasaka@life.kindai.ac.jp (H. Hayasaka).

https://doi.org/10.1016/j.bbrep.2021.101128
Received 14 August 2021; Received in revised form 2 September 2021; Accepted 2 September 2021
2405-5808/© 2021 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

The directed recruitment of cells by chemotactic factors is an important aspect of various biological processes, including wound healing, angiogenesis, the immune response, and cancer metastasis [1]. Chemokines control the recruitment and positioning of cells to the local tissue by inducing intracellular signaling via transmembrane G protein-coupled receptors (GPCRs) [2,3]. In lymphocyte migration, multiple chemokines, including CCL21/SLC, CCL19/ELC, CXCL12/stromal cell-derived factor 1 alpha, CXCL10/IP-10, and CXCL13/BLC, mediate chemokine gradient-dependent cell migration and contribute to efficient lymphocyte migration from the blood to the lymph nodes and Payer’s patches [4]. Both CCL21 and CCL19 bind to a common receptor, CCR7, which is critical for T cell trafficking through high endothelial venules in the lymph nodes and Payer’s patches [5,6]. CXCL12 is expressed in multiple tissues, including lymphoid tissues, the lungs, liver, and brain, and selectively binds to its receptors, CXCR4 and CXCR7, functioning as a chemoattractant and controlling efficient naïve lymphocyte migration in concert with CCR7 ligand chemokines [7,8]. CXCR4 is known as a major receptor in various biological processes, including leukocyte migration, maintenance of hematopoietic stem cell niches, tissue development, and cancer metastasis [9–11]. In contrast to CXCR4, CXCR7 only contributes to lymphocyte migration to a minor extent due to its low expression level on leukocyte cell surfaces under homeostatic conditions [12].

In recent years, it has been proposed that leukocyte migration is regulated by sequential waves of multiple chemoattractants, which propagate cell migration signals triggered by a primary stimulus to the surrounding cells. For example, neutrophils stimulated by formyl-Met-Leu-Phe (fMLP) extracellularly secrete a secondary chemoattractant, leukotriene B4 (LTB4), which further amplifies fMLP-mediated neutrophil migration [13]. Neutrophils also self-regulate their recruitment by the autocrine production of the chemokine, CXCL2, which further acts as a paracrine chemoattractant for other neutrophils [14]. Although the paracrine action of substances is a widespread concept in neutrophil recruitment to the site of inflammation, it is unknown whether a similar mechanism is involved in chemokine-dependent lymphocyte migration to secondary lymphoid tissues. In this study, we investigated whether...
CXCL12 stimulation induces the production of secondary substances from human T lymphocytes, which act as paracrine messengers to propagate chemokine signals to the surrounding cells.

2. Materials and methods

2.1. Cell culture and establishment of CXCR4-KO H9 cells

The human CD4+ T cell line, H9 (HTB-176), was obtained from the American Type Culture Collection and cultured in 10% (v/v) fetal calf serum (FCS; PAA Laboratories), 10 mM HEPES (Gibco), and 1 M sodium pyruvate in RPMI1640 medium (Sigma) containing 100 U/mL penicillin (Gibco), 100 μg/mL streptomycin (Gibco), 0.1 mM non-essential amino acids (Gibco), and 50 μM 2-mercaptoethanol (Sigma).

The CXCR4-knockout (KO) H9 cell line was established using the CRISPR-Cas9 system as follows. First, the double-stranded oligonucleotide corresponding to nucleotides 337–356 of the human CXCR4 gene (NM 0010084540.1) was subcloned to the plasmid vector GeneArt CRISPR (ThermoFisher Scientific) with orange fluorescent protein (OFP) and Cas9/Nuclease genes; then the plasmid was gene-introduced into H9 cells using a Nucleofector (Lonza). The transfected cells were expanded and subjected to cell sorting using a FACS Aria II cell sorter (BD Bioscience). The purified OFP-positive H9 cells were subjected to limiting dilution in 96-well plates to generate a monoclonal CXCR4-KO cell line. The CXCR4 sequences contained in the guide are described below.

**CXCR4 target top:** CACCTCAGATAACTACACCAGTTTT

**CXCR4 target bottom:** CCGTGTTAGTTCTGAGTGGTG

2.2. Flow cytometry

CXCR4 and CXCR7 expression was detected with 5 μg/mL allophycocyanin (APC)-labeled rat anti-human CD184 (CXCR4) monoclonal antibody (clone 12G5: BioLegend) and 10 μg/mL phycoerythrin (PE)-labeled mouse anti-human CXCR7 monoclonal antibody (clone 8F11-M16: BioLegend), respectively. CCR7 expression was detected with biotin-labeled rat anti-human CCR7 monoclonal antibody (clone 3D12: BD Biosciences, 1:20 dilution) and 1 μg/mL Dylight 649-labeled streptavidin (BioLegend). Binding of soluble chemokine chimeras containing the human immunoglobulin constant region (CXCR4-L2-Fc, CCL19-Fc, and control-Fc; gifts from Dr. K. Hieshima, Kindai University, Osaka, Japan [15]) to H9 cells was detected by staining with PE-conjugated goat antibody (Jackson Immuno Research, Inc.). The data analysis and interpretation were carried out using a BD LSRFortessa system and the FlowJo software (BD Biosciences).

2.3. RT-PCR analysis

Total RNA was purified using the RNA Basic Kit, and cDNA was synthesized using the Scriptase Basic cDNA-Kit (NIPPON Genetics Co., Ltd.). PCR was performed with KOD-FX Neo (TOYOBO Co., Ltd.), oligonucleotide primers, and 0.2 μg template cDNA. The amplified DNA products of CXCR7 (627-bp), CXCR4 (367-bp), CCR7 (530-bp), and beta-actin (838-bp) were analyzed by agarose gel electrophoresis. The signal intensities were determined using ImageJ software (NIH). The primer sequences used are described below.

**CXCR7 forward:** 5′-ATGGATCTGCATCTTCTTCTGA-3′
**CXCR7 reverse:** 5′-CAGGCAACTCCTCGTAGTGCTGT-3′
**CXCR4 forward:** 5′-AATTCTTCGTGCCCAACATCT-3′
**CXCR4 reverse:** 5′-GAGGGAATGAGACACACCT-3′
**CCR7 forward:** 5′-TGCTCTCTCATGCAAGCTGTC-3′
**CCR7 reverse:** 5′-GAGGCAGCCCGACCTCGTGAAG-3′

**Beta-actin forward:** 5′-ATCTGCGGACCACACATCTCAATGAGCTGC-3′
**Beta-actin reverse:** 5′-CGTCTACTCTCCTGTCGTGATCCACATCTG-3′

2.4. Preparation of conditioned cell culture medium

The cells in ice-cold PBS containing 5 mM MgCl2 were allowed to stand for 30 min on ice. Cells were then resuspended at 2 × 10^6 cells/mL with 100 ng/mL recombinant human CXCL12 (Sigma) or PBS containing 0.1% bovine serum albumin (BSA) and incubated for 30 min at 37°C. After centrifugation, the supernatant was collected and filtered with a 0.45-μm pore size filter and, subsequently, with a 0.22-μm filter (Millipore). The filtered medium was centrifuged for 20 min at 7500×g using Amicon Ultra-4 10 K centrifugal filter devices (Merck Millipore). The 20-fold concentrated conditioned medium (CM) of each treatment was used for the following experiments.

2.5. Transwell cell migration assay

CXCL12 or CCL19-dependent cell migration was performed with a transwell cell culture chamber with a membrane diameter of 6.5 mm and a pore size of 8-μm (Corning, NY, USA). The parental H9 and CXCR4-KO cells were fluorescently stained with 10 μM CFSE (Invitrogen) or 1 μM CytoRed (Dojindo, 1 μM), respectively, for 30 min at 37°C. The stained parental H9 alone, CXCR4-KO alone, or their 1:1 mixture was added to the upper chamber at 1 × 10^6 cells/well, and the chemokine solutions of 100 ng/mL recombinant human CCL19 (R & D Systems) or human CXCL12 (Sigma) in RPMI1640 containing 0.1% BSA were added to the lower layer. Alternatively, only CXCR4-KO cells were added to the upper chamber at 1 × 10^6 cells/well, and the parental H9 cells at 1 × 10^6 cells/well with CXCL12 were added to the lower chamber. After incubation for 2 h at 37°C in a CO2 incubator, the number of cells that had migrated to the lower chamber was analyzed by flow cytometry.

2.6. Time-lapse video microscopic analysis

Time-lapse analysis was performed with a real-time cell migration analyzer (EZ-TAXIScan; GE healthcare bioscience). The 20-fold concentrated CM of CXCL12-treated cells (CXCL12 CM) or that of the control treatment (control CM) were added at a ratio of 1:10 to the cell suspension at 1 × 10^8 cells/mL. Immediately after the addition of each CM, 1 μL of the cell suspension was loaded into each well of the microchamber, and 100 ng of recombinant human CCL21 (R & D Systems) was applied to the contra-wells. In some cases, 1 μL of 20-fold concentrated CXCL12 CM or control CM was applied to the contra-wells. The images of the migrating cells on cover glasses were automatically captured by a CCD camera for 2 h at 37°C. The qualitative analyses of cell migration were performed using FIJI Image J software (NIH).

2.7. Ethics statement

The experimental protocols were approved by the Ethics Review Committee of Kindai University. All experiments were conducted in accordance with the approved guidelines from Kindai University.

3. Results

3.1. CXCL12-stimulated cells enhanced CXCR4-KO cell migration

To assess the possibility that CXCL12-stimulated cells produce secondary chemokine attractants that affect surrounding cell migration, we examined the effect of CXCL12-stimulated parental H9 cells (WT) on the surrounding CXCR4-KO cells. Under flow cytometric analysis, CXCR4 expression in CXCR4-KO cells was almost undetectable, whereas CCR7 expression was comparable between the WT and the CXCR4-KO cells (Fig. 1A). We confirmed that the cell surface expression of CXCR7 was undetectable in both CXCR4-KO and WT cells. We found that CXCL12-Fc binding was significantly reduced in CXCR4-KO cells compared to WT
cells, suggesting the functional deficiency of CXCR4 in the CXCR4-KO cells (Fig. 1B). Conversely, CXCL12-Fc binding was moderately detected in CXCR4-KO cells, suggesting that CXCL12 binds to another receptor, rather than to CXCR4 or CXCR7, in H9 cells. Consistent with CCR7 expression in CXCR4-KO cells, the CCL19-Fc binding level in CXCR4-KO cells was comparable to that in the WT cells. Despite the lack of cell surface expression, modest CXCR7 signals were detected in both WT and CXCR4-KO cells by RT-PCR (Fig. 1C), suggesting that CXCR7 mRNA is expressed, but scarcely expressed on the cell surface as previously reported [16]. The CXCR4 mRNA expression in CXCR4-KO cells was decreased by about half compared to WT cells, indicating that CXCR4 expression was hampered at transcription and translation levels.

To examine the possibility that WT cells affect CXCR4-KO cell migration, we compared CXCR4-KO cell migration with or without WT cells. To this end, we stained WT cells and KO cells, respectively, with different fluorescent dyes and subjected them to CXCL12-dependent cell migration with either CXCR4-KO cells alone or with CXCR4-KO cells pre-mixed with WT cells (Fig. 2A). In the transwell cell migration assay, CXCR4-KO cell migration was significantly increased to approximately 2-fold when CXCR4-KO cells were mixed with WT cells. In contrast, the cell migration of WT cells to CXCL12 was not affected by the presence of KO cells. When CXCR4-KO cell migration was examined with or without WT cells in the lower layer chambers supplemented with CXCL12, no significant change in CXCR4-KO cell migration was observed, irrespective of the presence of WT cells (Fig. 2B). From the above results, we speculated that WT cells affect CXCR4-KO cell migration when they are in close proximity. In contrast, CCR7 ligand chemokine (CCL19)-dependent CXCR4-KO cell migration was not significantly affected by mixing with WT cells (Fig. 2C), suggesting that the WT cells stimulate CXCR4-KO cell migration, which is selectively increased in the presence of CXCL12.

3.2. CXCL12-processed cell culture medium affected CXCR4 KO cell migration

To investigate the possibility that CXCL12-stimulated WT cells secrete paracrine factors that promote CXCR4-KO cell migration, we examined the effect of a CM from WT cells on CXCR4-KO cell migration. We prepared a concentrated cell culture media of CXCL12-treated WT cells (CXCL12 CM) and a control BSA-treated CM (control CM) by centrifugation with a molecular weight cut-off of 10 K. As shown in Fig. 3, CXCL12-dependent CXCR4-KO cell migration increased when the cells were pre-incubated with CXCL12 CM, but not with the control CM (Fig. 3). In contrast, the CXCL12 CM significantly suppressed CXCR4-KO
cell migration in response to the CCR7 ligand, CCL21. These results suggest that CXCL12-treated WT cells secrete paracrine factors that promote CXCL12-dependent cell migration and suppress CCR7 ligand-dependent CXCR4-KO cell migration.

To gain insight into the mechanism underlying the CXCL12 CM’s role in cell migration, we examined whether the CXCL12 CM affected chemokine binding in CXCR4-KO cells. As shown in Fig. 4A, neither of the CMs affected the CCR7 expression, CXCL12-Fc binding, or CCL19-Fc binding, suggesting that the enhancing and suppressive effects on CXCR4 and CCR7-dependent cell migration, respectively, were not caused by changes in ligand–receptor binding.

Next, we examined the role of CXCL12 CM in migratory behavior (directionality, migration speed). The analysis revealed that the CXCL12 CM decreased the directionality (the ratio of the shortest distance from the origin to the end point of migration to the distance actually migrated) in CXCR4-KO cell migration compared to the control CM (Fig. 4B), but did not significantly affect the migration speed (Fig. 4C).
Fig. 4. The effects of the control-treated or CXCL12-treated CM on the CXCR4-KO cell migration behavior. (A) The CXCL12-Fc binding, CCL19-Fc binding, and CCR7 expression levels in CXCR4-KO cells after treatment with PBS (black), control CM (blue), or CXCL12 CM (red) were analyzed by flow cytometry. Gray histograms represent the binding level of Control-Fc or an isotype control antibody. (B) The trajectory of migrated CXCR4-KO cells in the presence of CXCL12-treated or control-treated CM. The representative results from seven independent experiments are shown. Each line shows the trajectory of individual cell (control-treated CM, n = 20 and CXCL12-treated CM, n = 18). (C) The directional migration (left) and migration speed (right) of the CXCR4-KO cells in response to the control-processed or the CXCL12-processed CM. The directionality (d/D) was calculated by the ratio of the shortest distance until the cell reached the end point and the distance actually traveled. In the control-processed CM, 122 cells were analyzed, and 124 cells were analyzed in the CXCL12-processed CM. (D) The directional migration (left) and migration speed (right) of CCL21-induced CXCR4-KO cell migration in the presence of control-processed CM or CXCL12-processed CM. In the PBS-treated CM, 100 cells were analyzed. 95 cells were analyzed in the control-treated CM and 80 cells were analyzed in the CXCL12-treated CM. The statistical difference was determined by two-tailed Mann-Whitney’s U test and depicted with *p < 0.05. NS, not significant. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
These results suggest that CXCL12 CM contains substances that change cell migration behavior. When CCL21 was used as a chemoattractant, both the directionality and the speed of cell migration was decreased in the CXCL12 CM (Fig. 4D), in agreement with the suppressive role of CXCL12 CM on CCR7 ligand-dependent cell migration (Fig. 3B).

4. Discussion

4.1. Secondary factors produced by T lymphocytes after CXCL12 stimulation

In this study, we found that the conditioned medium of CXCL12-treated cells promoted CXCR4-deficient cell chemotaxis, and the CXCL12 CM showed a suppressive effect on CCR7 ligand-dependent cell motility by affecting the directionality and speed of chemotaxis. These results support the idea that the CXCL12/CXCR4 axis causes the production of a signal-relay molecule that contributes to chemokine-dependent lymphocyte migration, similar to that reported in neutrophils [13].

We found that the CXCL12 CM promoted CXCR4-KO cell migration in the presence of CXCL12, suggesting that CXCR4-KO cells responded to CXCL12 via a CXCR4-binding receptor other than CXCR4. CXCR7 is known as a CXCL12 receptor with approximately 10 times higher affinity for CXCL12 than for CXCR4 [17,18], and mediates cell migration in certain T lymphocyte cell lines [19]. Numerous studies using cancer and primary cells have shown that CXCR7 is a functional receptor in various cell types [20,21], although each contribution of CXCR7 or CXCR4 to CXCL12-mediated cell migration is still controversial. Some studies have demonstrated that CXCR7 does not conjugate with G proteins, and it acts as a scavenger receptor that sequesters CKX12 to control the CXCL12 CXCR7 signaling pathways including arrestin recruitment [21]. In T lymphocytes, CXCR7 by itself does not activate G proteins, but it supports CXCR4 signaling through formation of CXCR4/CXCR7 complexes [24]. In HuT78-derived H9 cells used in this study, the cell surface CXCR7 expression was undetectable, as previously reported in HuT78 cells [25]. Therefore, the contribution of the CXCL12/CXCR7 axis to CXCR4-KO cell migration is considerably low. As a CXCL12 binding molecule other than CXCR7, a proteoglycan syndecan-4 is known to directly binds to CXCL12 and mediates CXCL12-dependent cell migration in CXCR4-KO cells [26].

We have not yet successfully identified the secondary factors produced by the CXCL12-treated lymphocytes. It has been reported that HuT78 cells efficiently migrate to IP-10/CXCL10, BCA 1/CXCL13, SLC/CCL21 and CTACK/CCL27 [28]. Our preliminary qPCR analysis of chemokine expression levels showed no significant changes in CCL19 and CCL27 after CXCL12 stimulation, and reduction of CCL21 and CXCL10 by nearly half. These results suggest that the above-mentioned chemokines are unlikely to be the secondary stimulants in the CXCL12 CM. Alternatively, substances with non-directional chemokinetic action on T lymphocytes, such as lysophosphatidic acid (LPA) or interferon-α2, may be involved in the phenomenon [29,30]. LPA enhances CXCL12-dependent chemotaxis and motility in T cells and has a dual action by promoting motility and directional cell migration or enhancing non-directed cell migration and inducing chemorepulsion in the presence of CCL21 [30–33]. On the other hand, we cannot exclude the possibility that the remaining CXCL12 in the concentrated CM caused CXCR4-KO cell migration, although the CM was prepared using an ultrafiltration membrane with a molecular weight cut-off of 10 K. Another possibility is that the remaining CXCL12 in the concentrated CM interacted with CXCL12 binding molecules such as syndecan-4, and then activated intracellular signaling in CXCR4-KO cells. Additional studies into the substances secreted by lymphocytes after CXCL12 stimulation will lead to the identification of the molecules which control the surrounding cell motility.

4.2. Biological significance of T lymphocyte-derived paracrine factors by CXCL12 stimulation

In our previous study, we demonstrated that the activation of CXCR4 signaling promotes CCR7 ligand-dependent in vitro T cell chemotaxis and in vivo cell trafficking to lymph nodes, suggesting that multiple chemoattractants function cooperatively to induce efficient leukocyte recruitment to target tissues [7,34]. In those studies, we demonstrated that CXCR4-mediated signaling induces CCR7 homo-dimerization and facilitates CCR7 ligand binding on the cell surface, and subsequently enhances the reactivity of the cells to CCR7 ligands [34,35]. Conversely, we found in this study that the paracrine factor induces an inhibitory signaling on CCR7-dependent chemotaxis in the absence of CXCR4-mediated signaling. According to these findings, we speculate that the paracrine factor may contribute to the maintenance of lymphocyte responsiveness to the first chemokine in settings of limited ligand availability in vivo, and prevent them from responding to other chemokines. Further investigation is needed to clarify whether the secondary paracrine factors contribute to propagate a chemokine signal to the surrounding cells, as has been demonstrated in neutrophils.

5. Conclusions

We revealed that CXCL12 contributes to lymphocyte navigation in concert with a secondary paracrine factor. Our results shed new light on the mechanisms for lymphocyte migration, particularly how chemokine-stimulated cells propagate cell migration signals to the surrounding cells.

Author contributions

K.K., M.E., and H.H. designed the experiments; K.K., M.E., and D.K. performed most of the experiments and analysis; H.H. wrote the manuscript. All authors reviewed and approved the final manuscript.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

This work is supported by the Ministry of Education, Culture, Sports, Science and Technology, Japan (Grant-in-Aid for Scientific Research, 19K07278 to H.H.), and an external funding support research grant from Graduating School of Science and Engineering, Kindai University, Japan. The authors gratefully thank Division of Joint Research Center, Kindai University for use of a flow cytometer. The authors would like to thank Enago (www.enago.jp) for the English language review.

References

[1] T. Jin, X. Xu, D. Hereld, Chemotaxis, chemokine receptors and human disease, Cytokine 44 (2008) 1–8.
[2] D.F. Legler, M. Thelen, New insights in chemokine signaling, F1000Res 7 (2018) 59.
[3] B. Moser, P. Loetscher, Lymphocyte traffic control by chemokines, Nat. Immunol. 2 (2001) 123–128.
[4] M. Miyasaka, T. Tanaka, Lymphocyte trafficking across high endothelial venules: dogmas and enigmas, Nat. Rev. Immunol. 4 (2004) 360–370.
[5] J.J. Campbell, E.P. Bowman, K. Murphy, K.R. Youngman, M.A. Siani, D. A. Thompson, et al., S–C–kine (SLC), a lymphocyte adhesion-triggering chemokine expressed by high endothelium, is an agonist for the MIP-3beta receptor CCR7, J. Cell Biol. 141 (1998) 1053–1059.
[6] R. Yoshida, M. Nagira, M. Kitaura, N. Imagawa, T. Imai, O. Yoshie, Secondary lymphoid-tissue chemokine is a functional ligand for the CC chemokine receptor CCR7, J. Biol. Chem. 273 (1998) 7118–7122.
[7] Z. Bai, H. Hayasaka, M. Kobayashi, W. Li, Z. Guo, M.H. Jung, et al., CXC chemokine ligand 12 promotes CCR7-dependent naive T cell trafficking to lymph nodes and Peyrer’s patches, J. Immunol. 182 (2009) 1267–1269.

[8] T. Okada, V.N. Ngo, E.H. Eklund, R. Forster, M. Lipp, D.R. Littman, et al., Chemokine requirements for B cell entry to lymph nodes and Peyrer’s patches, J. Exp. Med. 196 (2002) 65–75.

[9] K. De Filippo, S.M. Rankin, CXCR4, the master regulator of neutrophil trafficking in homeostasis and disease, Eur. J. Clin. Invest. 48 (Suppl 2) (2018), e12949.

[10] B.A. Teicher, S.P. Fricker, CXCL12 (SDF-1)/CXCR4 pathway in cancer, Clin. Canc. Res. 16 (2010) 2927–2931.

[11] T. Sugiyama, H. Kohara, M. Noda, T. Nagasawa, Maintenance of the hematopoietic stem cell pool by CXCL12/CXCR4 chemokine signaling in bone marrow stromal cell niches, Immunity 25 (2006) 977–988.

[12] R.D. Berahovich, B.A. Zabel, M.E. Penfold, S. Lewan, Y. Wang, Z. Mao, et al., CXCR7 protein is not expressed on human or mouse leukocytes, J. Immunol. 185 (2010) 5130–5139.

[13] P.V. Afonso, M. Janka-Junttila, Y.J. Lee, C.P. McCann, C.M. Oliver, K.A. Aamer, et al., LTβ4 is a signal-relay molecule during neutrophil chemotaxis, Dev. Cell 22 (2012) 1079–1091.

[14] J.L. Li, C.H. Lim, F.W. Tay, C.C. Goh, S. Devi, B. Malleret, et al., Neutrophils self-regulate immune complex-mediated cutaneous inflammation through CXCL2, J. Invest. Dermatol. 136 (2016) 416–424.

[15] N. Manjunath, P. Shankar, J. Wan, W. Weninger, M.A. Crowley, K. Hieshima, et al., Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes, J. Clin. Invest. 108 (2001) 871–878.

[16] T.N. Hartmann, V. Grabovsky, R. Pasvolsky, Z. Shulman, E.C. Buss, A. Spiegel, et al., A crossstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells, J. Leukoc. Biol. 84 (2008) 1130–1140.

[17] M.P. Crump, J.H. Gong, P. Loetscher, K. Rajarathnam, A. Amara, F. Arenzana-Seisdedos, et al., Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1, EMBO J. 16 (1997) 6996–7007.

[18] R. Kusunoki, R. Garty, M. Sakai, T. Takanami, H. Hasegawa, M. Yagasaki, et al., CXCR4 is expressed on human T lymphocytes and CD34+ cells, J. Leukoc. Biol. 84 (2008) 1287–1295.

[19] A. Levoye, K. Balabanian, B. Baleux, F. Bacherelle, B. Lagane, CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling, Blood 113 (2009) 6085–6093.

[20] S. Pinto, A. Martinez-Romero, J.E. O’Connor, R. Gil-Benzo, T. San-Miguel, L. Terradez, et al., Intracellular coexpression of CXCL12 and its chemokine receptors and their ligands in human melanoma cell lines and dynamic variations after xenotransplantation, BMC Canc. 14 (2014) 118.

[21] N. Charnaux, S. Brule, M. Hamon, T. Chaigneau, L. Saffar, C. Prost, et al., Syndecan-4 is a signaling molecule for stromal cell-derived factor-1 (SDF-1)/CXCL12, FEBS J. 272 (2005) 1937–1951.

[22] J.S. Chung, L.I. Shiue, M. Duvic, A. Pandya, P.D. Cruz Jr., K. Arizumi, Sezary syndrome cells overexpress CXCR4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-β on the cell surface, Blood 117 (2011) 3382–3396.

[23] M. Notobamiprodjo, S. Segerer, R. Huss, B. Hildebrandt, D. Soler, R. Djaifarzadeh, et al., CCR10 is expressed in cutaneous T-cell lymphoma, Int. J. Canc. 115 (2005) 641–647.

[24] G.R. Foster, S.H. Mazi, R. David, M. Jones, A. Datta, G. Lombardi, et al., IFN-α subtypes differentially affect human T cell motility, J. Immunol. 173 (2004) 1663–1670.

[25] H. Kanda, R. Newton, R. Klein, Y. Morita, M.D. Gunn, S.D. Rosen, Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs, Nat. Immunol. 9 (2008) 415–423.

[26] Y. Zhang, Y.C. Chen, M.F. Krummel, S.D. Rosen, Autotaxin, an ectoenzyme that produces lysophosphatidic acid stimulates polarization, motility, and transendothelial migration of naive T cells, J. Immunol. 189 (2012) 3914–3924.

[27] T. Kataoka, N. Kondo, Y. Ueda, T. Kinashi, Autotaxin produced by stromal cells can migrate into tissue at high concentrations, J. Immunol. 173 (2004) 1615–1622.

[28] S.A. Knowlden, T. Capece, M. Popovic, T.J. Chapman, F. Rezaee, M. Kim, et al., Regulation of T cell motility in vitro and in vivo by LPA and LPA2, PLoS One 9 (2014), e101655.

[29] H. Hayasaka, D. Kobayashi, H. Yoshimura, E.E. Nakayama, T. Shioda, M. Miyasaka, The HIV-1 Gp120/CXCR4 axis promotes CCR7 ligand-dependent CD4 T cell migration: CCR7 homo- and CCR7/CXCR4 hetero-oligomer formation as a possible mechanism for up-regulation of functional CCR7, PLoS One 10 (2015), e0117454.

[30] D. Kobayashi, M. Endo, H. Ochi, H. Hojo, M. Miyasaka, H. Hayasaka, Regulation of CCR7-dependent cell migration through CCR7 homodimer formation, Sci. Rep. 7 (2017) 8536.